BNR - Burning Rock Biotech Ltd
3.6349
-0.138 -3.783%
Share volume: 3,529
Last Updated: 04-07-2025
Healthcare/Services – Health:
1.03%
PREVIOUS CLOSE
CHG
CHG%
$3.77
-0.14
-0.04%
Fundamental analysis
17%
Profitability
18%
Dept financing
0%
Liquidity
0%
Performance
25%
Performance
5 Days
-7.98%
1 Month
-25.82%
3 Months
-42.94%
6 Months
-42.94%
1 Year
-42.94%
2 Year
-42.94%
Key data
Stock price
$3.63
DAY RANGE
$3.57 - $3.95
52 WEEK RANGE
$3.57 - $6.50
52 WEEK CHANGE
-$42.94
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-28-2025
Company detail
CEO: Yu S. Han
Region: US
Website: brbiotech.com
Employees: 1,390
IPO year: 2020
Issue type:
Market: XNAS
Industry: Healthcare/Services – Health
Sector: Services
Region: US
Website: brbiotech.com
Employees: 1,390
IPO year: 2020
Issue type:
Market: XNAS
Industry: Healthcare/Services – Health
Sector: Services
Burning Rock Biotech Limited primarily develops and provides cancer therapy selection tests in the People's Republic of China. Its products include OncoScreen IO, a pan-cancer test for tissue samples; OncoCompass IO, the corresponding test for liquid biopsy samples. The company also offers LungCore for lung cancer, ProstrateCore for prostrate cancer, BreastCore for breast cancer, LymphPlasma for lymphomas, and ThyroCare for thyroid cancer.
Recent news
